Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NexgenRxNEGXF 46 EV-to-EBITDA is 9.64 as of Aug. 14, 2026, which is 5% below its 10-year median of 10.17. GuruFocus rates NEGXF with a GF Score™ of 46/100 and a GF Value™ of $0.27 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 511 Healthcare Providers & Services companies, NexgenRx ranks better than 56.56% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, NexgenRx's enterprise value is $26.66 Mil.
NexgenRx's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $2.76 Mil. Therefore, NexgenRx's EV-to-EBITDA for today is 9.64.
The historical rank and industry rank for NexgenRx's EV-to-EBITDA or its related term are showing as below:
NEGXF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -122.63 Med: 10.17 Max: 188.8
Current: 10.51
During the past 13 years, the highest EV-to-EBITDA of NexgenRx was 188.80. The lowest was -122.63. And the median was 10.17.
NEGXF's EV-to-EBITDA is ranked better than 56.56% of 511
companies
in the Healthcare Providers & Services industry
Industry Median: 10.76
vs NEGXF: 10.51
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NexgenRx's share price for today is $0.325.
NexgenRx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.018.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for NexgenRx's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, NexgenRx's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NexgenRx EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NexgenRx's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where NexgenRx's EV-to-EBITDA falls into.
NexgenRx's current Enterprise Value is $26.66 Mil.
NexgenRx's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.76 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NexgenRx (NEGXF) has a EV-to-EBITDA of 9.64 as of Aug. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on NexgenRx. This is near median its historical median of 10.17. According to the industry distribution chart, NexgenRx ranks #222 out of 511 companies in the Healthcare Providers & Services industry, placing it in the top 43.4%.
Is NexgenRx's EV-to-EBITDA too high?
NexgenRx's current EV-to-EBITDA of 9.64 is near median its 10-year median of 10.17. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.76. NexgenRx's value of 9.64 is 10.4% below this industry median. Based on the distribution chart, NexgenRx ranks #222 out of 511 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, NexgenRx has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NexgenRx's EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, NexgenRx ranks #222 out of 511 companies for EV-to-EBITDA. This puts NexgenRx in the upper half of its industry. The industry median EV-to-EBITDA is 10.76. NexgenRx's value of 9.64 is 10.4% below this benchmark. While the company's 10-year median is 10.17 vs. the industry median of 10.76, NexgenRx has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.76, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NexgenRx's current EV-to-EBITDA of 9.64 is 10.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on NexgenRx. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NexgenRx's current EV-to-EBITDA is 9.64, which is near median its own 10-year median of 10.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexgenRx stock overvalued right now?
Based on GuruFocus' analysis, NexgenRx (NEGXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $0.33 — trading 20.4% above its estimated fair value. The current EV-to-EBITDA is 9.64, which is near median its 10-year median of 10.17 and 10.4% below the Healthcare Providers & Services industry median of 10.76. NexgenRx's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For NexgenRx (NEGXF), the current EV-to-EBITDA is 9.64 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NexgenRx (NEGXF) Overvalued in 2026?
Based on GuruFocus' analysis, NexgenRx stock appears to be overvalued.
The current stock price of $0.33 is trading 20.4% above its estimated GF Value™ of $0.27.
GuruFocus considers NexgenRx to be Modestly Overvalued.
Key valuation signals for NEGXF:
EV-to-EBITDA: 9.64 (near median its 10-year median of 10.17)
GF Value™: $0.27 vs. price of $0.33 (20.4% above fair value)
Industry Position: 10.4% below the Healthcare Providers & Services median (#222 of 511)
No single metric tells the full story. See the NEGXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.
46GF Score
Get the complete analysis for NEGXF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEGXF has been successfully added to your 
